People | April 22, 2026
ECI taps industry veteran Khalid Raja to drive strategic growth
Move comes amid rising regulatory pressures
Move comes amid rising regulatory pressures
Pharma giant targets new standards of care
By cutting pain crises & boosting haemoglobin
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
A decision is expected by August 17, 2026 under the Prescription Drug User Fee Act timeline
Targets high-growth eye care expansion push
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
C-CAMP–Imperial College London partnership to boost biotech research, startup exchange, and translational innovation through a five-year collaboration
The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
